Sign in Subscribe
Pharmaceutical industry

Dia-B Tech Attracts Global Pharmaceutical Interest for Potential Diabetes Treatments

Strategic Insights

— 2 min read

Dia-B Tech, an Australian-based medical research company, has sparked interest from global pharmaceutical companies for its potential diabetes treatments. The company, which listed on the Australian Stock Exchange today, is being courted by major players for partnerships or licensing deals. Its project, led by Professor Paul Zimmet, has been approached by a global pharmaceutical group and one of Europe's largest biotechnology companies to collaborate on developing ISF402, a naturally occurring peptide that enhances insulin action and lowers blood glucose levels.

Key Takeaways:

  • Dia-B Tech, a medical research company, has attracted interest from global pharmaceutical companies for its potential diabetes treatments.
  • The company's project, led by Professor Paul Zimmet, has been approached by a global pharmaceutical group and one of Europe's largest biotechnology companies for partnerships or licensing deals.
  • ISF402, a naturally occurring peptide, has been shown to enhance insulin action and lower blood glucose levels in rats, with human trials planned for the middle of this year.
  • Dia-B Tech will operate with a virtual structure to minimize corporate costs, outsourcing much of its research and development.
  • The company has secured $6 million in funding through an initial public offering (IPO) at 20 cents per share, with 30 million shares issued.
  • Investors were unfazed by the lack of human trials for the company's projects, with the IPO heavily oversubscribed.
  • Dia-B Tech's projects aim to target Type 1 and 2 diabetes and diabetes complications, affecting over 190 million people worldwide.
  • The company was previously owned by Cardia Technologies, which withdrew funding plans due to the September 11 terrorist attacks in 2001, but later took the project as a wholly owned subsidiary.

Statistics:

  • Dia-B Tech listed on the Australian Stock Exchange today.
  • The company raised $6 million through an IPO priced at 20 cents per share.
  • 30 million shares were issued as part of the IPO.
  • ISF402 has been shown to enhance insulin action and lower blood glucose levels in rats.
  • Human trials for ISF402 are planned for the middle of this year.
  • Dia-B Tech's projects aim to address Type 1 and 2 diabetes and diabetes complications, affecting over 190 million people worldwide.
  • The company will operate with a virtual structure to minimize corporate costs.

Sources:

  • Melbourne Stock Exchange listing for Dia-B Tech. [1]
  • Interview with Professor Paul Zimmet, Managing Director of Dia-B Tech.
  • Company press release announcing listing on Australian Stock Exchange.
  • Cardia Technologies statement regarding withdrawal of funding plans due to September 11 terrorist attacks in 2001.

Read more